Please assess the completion status of the following clinical trial:

Trial Title: A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced measurable or non-measurable solid tumors~* Adequate bone marrow function~* Adequate liver function~* Adequate renal function~* Be able and willing to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures~Exclusion Criteria:~* Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of first dose of study medication~* Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, hemoptysis or melena in the past 6 months~* Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolus; or any other active thromboembolic event~* QTc prolongation defined as QTc \>450 msec~* Patients with known brain metastasis~* Patients with peritoneal carcinosis at risk of bleeding~* Major surgical procedure within 4 weeks of treatment~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).